Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100® Study in Hospitalized Patients With COVID-19

Stock Information for Daxor Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Daxor Corporation

New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100(TM))
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.